Exploring a genetic regulator of cancer-related EGFR activity in fish
Official title: Identification and Characterization of a Endogenous EGFR Regulatory Locus in Xiphophorus Genome
Funded at Texas State University · NIH-10296895 · Data updated 2026-11-12
This study is looking at how a certain gene in Xiphophorus fish might help control a protein linked to cancer, with the hope that what we learn could lead to better treatments for people with cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas State University NIH-funded |
| Lab location | 1 site (San Marcos, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2021 |
| Award (this year) | $451,447 |
| NIH project number | 2R15CA223964-02A1 |
| Project ID | NIH-10296895 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers associated with EGFR activity, particularly those who have shown resistance to current EGFR-targeted therapies.
✕Less likely to help
Patients with cancers not related to EGFR or those who do not have a genetic predisposition to EGFR-driven malignancies may not benefit from this research.
What this research studies
This research investigates the role of a specific genetic regulator in the Xiphophorus fish that may control the activity of the epidermal growth factor receptor (EGFR), which is linked to various cancers. By studying the interactions between this regulator and the oncogenic form of EGFR, the research aims to uncover new therapeutic strategies for cancer treatment. The approach involves genetic mapping and functional studies to understand how this regulator can inhibit cancerous activity. Patients may benefit from insights gained that could lead to improved cancer therapies targeting EGFR.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for cancers driven by EGFR, potentially improving patient outcomes.
How similar studies have gone: While the specific approach of characterizing a genetic regulator in Xiphophorus is novel, similar studies targeting EGFR in other contexts have shown promise in developing effective cancer therapies.
Where this research is happening
-
Texas State University
San Marcos, United States Active
Researchers
- Principal investigator: Lu, Yuan — Texas State University
- Study coordinator: Lu, Yuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.